Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform

Autor: Joy Martinez, Heidi Contreras, Edwin R. Manuel, Tae Hyuk Kang, Vu H. Nguyen, Teodora Kaltcheva, Mindy Kha, Qiao Zhou, Xiwei Wu, Don J. Diamond, Yuriy Shostak, Flavia Chiuppesi, Felix Wussow, Angelina Iniguez, Roman Levytskyy, Marcela d'Alincourt Salazar, Nancy D. Ebelt, Jenny Nguyen, Thomas F. Rogers, Yoonsuh Park
Rok vydání: 2020
Předmět:
0301 basic medicine
Protective immunity
Modified vaccinia Ankara
COVID-19 Vaccines
Live attenuated vaccines
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Science
viruses
Genetic Vectors
General Physics and Astronomy
Vaccinia virus
Biology
Adaptive Immunity
Antibodies
Viral
Vaccines
Attenuated
complex mixtures
General Biochemistry
Genetics and Molecular Biology
Article
law.invention
03 medical and health sciences
Mice
0302 clinical medicine
Immune system
Antigen
law
Animals
Coronavirus Nucleocapsid Proteins
Humans
Vector (molecular biology)
Antigens
Viral
Immunity
Cellular
Vaccines
Synthetic
Multidisciplinary
SARS-CoV-2
Viral Vaccines
General Chemistry
biochemical phenomena
metabolism
and nutrition
Phosphoproteins
Virology
Antibodies
Neutralizing
030104 developmental biology
Viral infection
030220 oncology & carcinogenesis
Spike Glycoprotein
Coronavirus
Recombinant DNA
biology.protein
Antibody
Zdroj: Nature Communications
Nature Communications, Vol 11, Iss 1, Pp 1-16 (2020)
ISSN: 2041-1723
Popis: Modified Vaccinia Ankara (MVA) is a highly attenuated poxvirus vector that is widely used to develop vaccines for infectious diseases and cancer. We demonstrate the construction of a vaccine platform based on a unique three-plasmid system to efficiently generate recombinant MVA vectors from chemically synthesized DNA. In response to the ongoing global pandemic caused by SARS coronavirus-2 (SARS-CoV-2), we use this vaccine platform to rapidly produce fully synthetic MVA (sMVA) vectors co-expressing SARS-CoV-2 spike and nucleocapsid antigens, two immunodominant antigens implicated in protective immunity. We show that mice immunized with these sMVA vectors develop robust SARS-CoV-2 antigen-specific humoral and cellular immune responses, including potent neutralizing antibodies. These results demonstrate the potential of a vaccine platform based on synthetic DNA to efficiently generate recombinant MVA vectors and to rapidly develop a multi-antigenic poxvirus-based SARS-CoV-2 vaccine candidate.
Chiuppesi et al. demonstrate the use of a synthetic poxvirus-based platform to rapidly generate multi-antigenic vaccine candidates expressing spike and nucleocapsid antigens of SARS-CoV-2. Immunization of mice stimulates potent antigen-specific humoral and cellular immune responses, including neutralizing antibodies.
Databáze: OpenAIRE
Externí odkaz: